Log in

Relevant bibliographies by topics / Quinolone

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Quinolone'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Quinolone.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Quinolone"

1

Shoji, Taku, Mutsumi Takeuchi, Mayumi Uda, Yukino Ariga, Akari Yamazaki, Ryuta Sekiguchi, and Shunji Ito. "Synthesis of Azuleno[2,1-b]quinolones and Quinolines via Brønsted Acid-Catalyzed Cyclization of 2-Arylaminoazulenes." Molecules 28, no. 15 (July 31, 2023): 5785. http://dx.doi.org/10.3390/molecules28155785.

Full text

Abstract:

Quinolone and quinoline derivatives are frequently found as substructures in pharmaceutically active compounds. In this paper, we describe a procedure for the synthesis of azuleno[2,1-b]quinolones and quinolines from 2-arylaminoazulene derivatives, which are readily prepared via the aromatic nucleophilic substitution reaction of a 2-chloroazulene derivative with several arylamines. The synthesis of azuleno[2,1-b]quinolones was established by the Brønsted acid-catalyzed intramolecular cyclization of 2-arylaminoazulene derivatives bearing two ester groups at the five-membered ring. The halogenative aromatization of azuleno[2,1-b]quinolones with POCl3 yielded azuleno[2,1-b]quinolines with a chlorine substituent at the pyridine moiety. The aromatic nucleophilic substitution reaction of azuleno[2,1-b]quinolines bearing chlorine substituent with secondary amines was also investigated to afford the aminoquinoline derivatives. These synthetic methodologies reported in this paper should be valuable in the development of new pharmaceuticals based on the azulene skeleton.

APA, Harvard, Vancouver, ISO, and other styles

2

Ehrhardt, A. F., and C. C. Sanders. "Structure-activity studies of quinolone-penems in genetically defined strains of Escherichia coli." Antimicrobial Agents and Chemotherapy 41, no. 11 (November 1997): 2570–72. http://dx.doi.org/10.1128/aac.41.11.2570.

Full text

Abstract:

Quinolonyl-beta-lactam antimicrobial agents (QLAs) contain quinolones chemically linked to beta-lactams, although the impact of linkage is poorly understood. Genetically defined Escherichia coli strains were used to determine structure-activity characteristics of three quinolone-penem QLAs. Results suggest that the leaving group resulting from beta-lactam hydrolysis may not be free quinolone.

APA, Harvard, Vancouver, ISO, and other styles

3

Kumagai, Y., J. I. Kato, K. Hoshino, T. Akasaka, K. Sato, and H. Ikeda. "Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene." Antimicrobial Agents and Chemotherapy 40, no. 3 (March 1996): 710–14. http://dx.doi.org/10.1128/aac.40.3.710.

Full text

Abstract:

Escherichia coli quinolone-resistant strains with mutations of the parC gene, which codes for a subunit of topoisomerase IV, were isolated from a quinolone-resistant gyrA mutant of DNA gyrase. Quinolone-resistant parC mutants were also identified among the quinolone-resistant clinical strains. The parC mutants became susceptible to quinolones by introduction of a parC+ plasmid. Introduction of the multicopy plasmids carrying the quinolone-resistant parC mutant gene resulted in an increase in MICs of quinolones for the parC+ and quinolone-resistant gyrA strain. Nucleotide sequences of the quinolone-resistant parC mutant genes were determined, and missense mutations at position Gly-78, Ser-80, or Glu-84, corresponding to those in the quinolone-resistance-determining region of DNA gyrase, were identified. These results indicate that topoisomerase IV is a target of quinolones in E. coli and suggest that the susceptibility of E. coli cells to quinolones is determined by sensitivity of the targets, DNA gyrase and topoisomerase IV.

APA, Harvard, Vancouver, ISO, and other styles

4

Noble, Christian G., Faye M. Barnard, and Anthony Maxwell. "Quinolone-DNA Interaction: Sequence-Dependent Binding to Single-Stranded DNA Reflects the Interaction within the Gyrase-DNA Complex." Antimicrobial Agents and Chemotherapy 47, no. 3 (March 2003): 854–62. http://dx.doi.org/10.1128/aac.47.3.854-862.2003.

Full text

Abstract:

ABSTRACT We have investigated the interaction of quinolones with DNA by a number of methods to establish whether a particular binding mode correlates with quinolone potency. The specificities of the quinolone-mediated DNA cleavage reaction of DNA gyrase were compared for a number of quinolones. Two patterns that depended on the potency of the quinolone were identified. Binding to plasmid DNA was examined by measuring the unwinding of pBR322 by quinolones; no correlation with quinolone potency was observed. Quinolone binding to short DNA oligonucleotides was measured by surface plasmon resonance. The quinolones bound to both single- and double-stranded oligonucleotides in an Mg2+-dependent manner. Quinolones bound to single-stranded DNA with a higher affinity, and the binding exhibited sequence dependence; binding to double-stranded DNA was sequence independent. The variations in binding in the presence of metal ions showed that Mg2+ promoted tighter, more specific binding to single-stranded DNA than softer metal ions (Mn2+ and Cd2+). Single-stranded DNA binding by quinolones correlated with the in vitro quinolone potency, indicating that this mode of interaction may reflect the interaction of the quinolone with DNA in the context of the gyrase-DNA complex.

APA, Harvard, Vancouver, ISO, and other styles

5

Horta, Pedro, Marta S. C. Henriques, Elisa M. Brás, Fernanda Murtinheira, Fátima Nogueira, Paul M. O’Neill, José A. Paixão, Rui Fausto, and Maria L. S. Cristiano. "On the ordeal of quinolone preparation via cyclisation of aryl-enamines; synthesis and structure of ethyl 6-methyl-7-iodo-4-(3-iodo-4-methylphenoxy)-quinoline-3-carboxylate." Pure and Applied Chemistry 89, no. 6 (June 27, 2017): 765–80. http://dx.doi.org/10.1515/pac-2016-1119.

Full text

Abstract:

AbstractRecent studies directed to the design of compounds targeting the bc1 protein complex of Plasmodium falciparum, the parasite responsible for most lethal cases of malaria, identified quinolones (4-oxo-quinolines) with low nanomolar inhibitory activity against both the enzyme and infected erythrocytes. The 4-oxo-quinoline 3-ester chemotype emerged as a possible source of potent bc1 inhibitors, prompting us to expand the library of available analogs for SAR studies and subsequent lead optimization. We now report the synthesis and structural characterization of unexpected ethyl 6-methyl-7-iodo-4-(3-iodo-4-methylphenoxy)-quinoline-3-carboxylate, a 4-aryloxy-quinoline 3-ester formed during attempted preparation of 6-methyl-7-iodo-4-oxo-quinoline-3-carboxylate (4-oxo-quinoline 3-ester). We propose that the 4-aryloxy-quinoline 3-ester derives from 6-methyl-7-iodo-4-hydroxy-quinoline-3-carboxylate (4-hydroxy-quinoline 3-ester), the enol form of 6-methyl-7-iodo-4-oxo-quinoline-3-carboxylate. Formation of the 4-aryloxy-quinoline 3-ester confirms the impact of quinolone/hydroxyquinoline tautomerism, both on the efficiency of synthetic routes to quinolones and on pharmacologic profiles. Tautomers exhibit different cLogP values and interact differently with the enzyme active site. A structural investigation of 6-methyl-7-iodo-4-oxo-quinoline-3-carboxylate and 6-methyl-7-iodo-4-hydroxy-quinoline-3-carboxylate, using matrix isolation coupled to FTIR spectroscopy and theoretical calculations, revealed that the lowest energy conformers of 6-methyl-7-iodo-4-hydroxy-quinoline-3-carboxylate, lower in energy than their most stable 4-oxo-quinoline tautomer by about 27 kJ mol−1, are solely present in the matrix, while the most stable 4-oxo-quinoline tautomer is solely present in the crystalline phase.

APA, Harvard, Vancouver, ISO, and other styles

6

López, Y., M. Tato, P. Espinal, F. Garcia-Alonso, D. Gargallo-Viola, R. Cantón, and J. Vila. "In VitroActivity of Ozenoxacin against Quinolone-Susceptible and Quinolone-Resistant Gram-Positive Bacteria." Antimicrobial Agents and Chemotherapy 57, no. 12 (September 30, 2013): 6389–92. http://dx.doi.org/10.1128/aac.01509-13.

Full text

Abstract:

ABSTRACTIn vitroactivity of ozenoxacin, a novel nonfluorinated topical (L. D. Saravolatz and J. Leggett, Clin. Infect. Dis.37:1210–1215, 2003) quinolone, was compared with the activities of other quinolones against well-characterized quinolone-susceptible and quinolone-resistant Gram-positive bacteria. Ozenoxacin was 3-fold to 321-fold more active than other quinolones. Ozenoxacin could represent a first-in-class nonfluorinated quinolone for the topical treatment of a broad range of dermatological infections.

APA, Harvard, Vancouver, ISO, and other styles

7

Adriaenssens, Niels, Robin Bruyndonckx, Ann Versporten, Niel Hens, Dominique L. Monnet, Geert Molenberghs, Herman Goossens, et al. "Consumption of quinolones in the community, European Union/European Economic Area, 1997–2017." Journal of Antimicrobial Chemotherapy 76, Supplement_2 (July 1, 2021): ii37—ii44. http://dx.doi.org/10.1093/jac/dkab176.

Full text

Abstract:

Abstract Objectives Data on quinolone consumption in the community were collected from 30 EU/European Economic Area (EEA) countries over two decades. This article reviews temporal trends, seasonal variation, presence of change-points and changes in the composition of main subgroups of quinolones. Methods For the period 1997–2017, data on consumption of quinolones, i.e. ATC group J01M, in the community and aggregated at the level of the active substance, were collected using the WHO ATC/DDD methodology (ATC/DDD index 2019). Consumption was expressed in DDD per 1000 inhabitants per day and in packages per 1000 inhabitants per day. Quinolone consumption was analysed by subgroups based on pharmacokinetic profile, and presented as trends, seasonal variation, presence of change-points and compositional changes. Results In 2017, quinolone consumption in the community expressed in DDD per 1000 inhabitants per day varied by a factor of 8.2 between countries with the highest (Bulgaria) and the lowest (Norway) consumption. The second-generation quinolones accounted for >50% of quinolone consumption in most countries. Quinolone consumption significantly increased up to 2001, and did not change significantly afterwards. Seasonal variation increased significantly over time. Proportional consumption of third-generation quinolones significantly increased over time relative to that of second-generation quinolones, while proportional consumption of both third- and second-generation quinolones significantly increased relative to that of first-generation quinolones. Levofloxacin and moxifloxacin represented >40% of quinolone consumption in the community in southern EU/EEA countries. Conclusions Quinolone consumption in the community is no longer increasing in the EU/EEA, but its seasonal variation continues to increase significantly as is the proportion of quinolones to treat respiratory infections.

APA, Harvard, Vancouver, ISO, and other styles

8

McGee, Edoabasi U., Essie Samuel, Bernadett Boronea, Nakoasha Dillard, Madison N. Milby, and Susan J. Lewis. "Quinolone Allergy." Pharmacy 7, no. 3 (July 19, 2019): 97. http://dx.doi.org/10.3390/pharmacy7030097.

Full text

Abstract:

Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-reactivity, and management of allergic reactions. Although the incidence of quinolone allergy is still lower than beta-lactams, it has been increasingly reported in recent decades, most likely from its expanded use and the introduction of moxifloxacin. Thorough patient history remains essential in the evaluation of quinolone allergy. Many diagnostic tools have been investigated, but skin tests can yield false-positive results and in vitro tests have not been validated. The drug provocation test is considered the test of choice to confirm a quinolone allergy but is not without risk. Evidence regarding cross-reactivity among the quinolones is limited and conflicting. Quinolone allergy can be manifested either as an immediate or delayed reaction, but is not uniform across the class, with moxifloxacin posing the highest risk of anaphylaxis. Quinolone should be discontinued when an allergic reaction occurs and avoided in future scenarios, but desensitization may be warranted if no alternatives are available.

APA, Harvard, Vancouver, ISO, and other styles

9

Law, Dennis KS, Michelle Shuel, Sadjia Bekal, Elizabeth Bryce, and Raymond SW Tsang. "Genetic Detection of Quinolone Resistance inHaemophilus parainfluenzae: Mutations in the Quinolone Resistance-Determining Regions ofgyrA andparC." Canadian Journal of Infectious Diseases and Medical Microbiology 21, no. 1 (2010): e20-e22. http://dx.doi.org/10.1155/2010/525919.

Full text

Abstract:

The quinolone resistance-determining regions ofgyrA andparC of both quinolone-sensitive and quinolone-resistantHaemophilus parainfluenzaestrains were amplified and sequenced. Similar toHaemophilus influenzae, resistance to quinolones inH parainfluenzaeis associated with mutations in the quinolone resistance-determining regions of bothgyrA andparC. The present study discusses the importance of this finding.

APA, Harvard, Vancouver, ISO, and other styles

10

Wang, Xiaoli, Tao Guo, Yunbo Wei, Guiju Xu, Na Li, Jinhong Feng, and Rusong Zhao. "Determination of Quinolone Antibiotic Residues in Human Serum and Urine Using High-Performance Liquid Chromatography/Tandem Mass Spectrometry." Journal of Analytical Toxicology 43, no. 7 (May 16, 2019): 579–86. http://dx.doi.org/10.1093/jat/bkz034.

Full text

Abstract:

Abstract Quinolone antibiotic residues may pose potential threat to human health. A rapid and sensitive method was developed for the determination of quinolone residues in human serum and urine. After solid phase extraction (SPE) process, eight quinolone residues were analyzed by high-performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) using ciprofloxacin-d8 as the internal standard. The relative standard deviation of intra-day and inter-day precision for the eight quinolones were less than 7.52% and the accuracies ranged from 95.8% to 103% in human serum, and from 94.1% to 104% in human urine. The extraction recoveries for the eight quinolones varied from 80.2% to 113% in human serum and 83.4% to 117% in human urine. The limit of detection for the eight quinolones was 0.50–1.00 ng/mL. Quinolone antibiotic residues in human serum and urine from 12 volunteers were successfully analyzed with the validated method. The SPE-HPLC-MS/MS method was useful for accurate determination of quinolone antibiotic residues in human body.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Quinolone"

1

Meola, Alain. "Les quinolones : étude chimique et pharmacologique, synthèse." Bordeaux 2, 1991. http://www.theses.fr/1991BOR2P090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Laurens, Gabrielle. "Quinolones et choc anaphylactique : à propos d'un bilan réalisé au Centre régional de pharmacovigilance du Languedoc-Roussillon." Paris 5, 1992. http://www.theses.fr/1992PA05P158.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ballesté, Delpierre Clara Celia. "Quinolone resistance acquisition and impact on virulence in Salmonella enterica: a cost-benefit matter." Doctoral thesis, Universitat de Barcelona, 2015. http://hdl.handle.net/10803/396155.

Full text

Abstract:

Infections due to Salmonella enterica are of great concern worldwide as they represent an important cause of morbidity and mortality. Resistance to antibiotics used to treat salmonellosis has emerged along the years, and thus, the treatment of choice has been changing in order to adapt to the new features of the circulating pathogens causing disease. Currently, fluoroquinolones, mainly represented by ciprofloxacin and ofloxacin, are widely used to treat this kind of infections although other antimicrobial classes as well as new generations of fluoroquinolones are sometimes required when treatment failure occurs. This situation is mainly due to the rise in the number of isolates showing nalidixic acid resistance associated with a decrease in the susceptibility to fluoroquinolones (e.g. ciprofloxacin). Moreover, the spread of multidrug resistant isolates carrying several resistance plasmid or chromosomally-located determinants also explains, in part, the decrease in the efficacy of the current treatment and represents an important issue. Despite this trend, a low frequency of fluoroquinolone-resistant Salmonella enterica isolates are still reported in the literature, a fact that has been the object of attention in our research group. In order to explain the current scene, we have hypothesized a presumable link between quinolone-resistance acquisition and the decrease in the virulence features among this species. This PhD thesis addresses the context of Salmonella from different perspectives, including an epidemiological approach as well as in vitro models in order to understand the biology of this pathogen and its relation with quinolone resistance. In order to develop our hypothesis, the following specific objectives were defined: 1) Evaluation of the clonal relatedness of S. Enteritidis and S. Typhimurium clinical isolates using two different typing techniques, 2) Analysis of the outer-membrane subproteome of S. Typhimurium SL1344, 3) Investigation of the molecular mechanisms of quinolone resistance and their regulation, 4) Assessment of virulence-related properties in clinical and in vitro-selected mutants of Salmonella enterica isolates presenting different degrees of susceptibility/resistance to quinolones, 5) Identification of novel genes potentially involved in quinolone resistance and/or virulence in S. Typhimurium, 6) Genome comparison of S. Typhimurium isolates causing invasive versus non-invasive salmonellosis from different geographical areas. These objectives have been fulfilled in 5 papers, a manuscript and additional results.
Las infecciones debidas a Salmonella enterica son de gran relevancia clínica ya que representan una importante causa de mortalidad y morbilidad en todo el mundo. Debido a la aparición de resistencia a los antibióticos utilizados para el tratamiento de la salmonelosis, la terapia de elección ha ido cambiando con el tiempo para adaptarse a las nuevas características de los patógenos circulantes causantes de la enfermedad. Actualmente, las fluoroquinolonas, representadas mayoritariamente por la ciprofloxacina y ofloxacina, son los antibióticos más usados contra estas infecciones, aunque en algunos casos es necesario recurrir a otras familias de antibióticos. Esto es debido al aumento en el número de casos resistentes al ácido nalidíxico, asociado a un descenso en la sensibilidad a las fluoroquinolonas, como la ciprofloxaciona. A pesar de esta tendencia, el número de casos reportados de Salmonella enterica altamente resistente a fluoroquinolonas permanece bajo. El estudio de esta inusual situación es una de las líneas de nuestro grupo de investigación siendo la hipótesis de partida la existencia de un vínculo entre adquisición de resistencia a quinolonas y una disminución de las características vinculadas a la virulencia en esta especie. La presente tesis doctoral aborda el contexto de la Salmonella desde diferentes perspectivas, incluyendo una aproximación epidemiológica así como modelos in vitro para entender la biología de este patógeno y su relación con la resistencia a quinolonas. Este trabajo incluye 5 artículos científicos, un manuscrito y resultados adicionales que responden a los siguientes objetivos: 1) Evaluación de la relación clonal entre aislados clínicos de S. Enteritidis y S. Typhimurium mediante el uso de dos técnicas distintas; 2) Análisis del subproteoma de la membrana externa de S. Typhimurium SL1344; 3) Investigación de los mecanismos moleculares de resistencia a quinolonas y de su regulación; 4) Evaluación de las propiedades relacionadas con la virulencia en aislados clínicos así como en mutantes seleccionados in vitro de Salmonella enterica con diferentes niveles de sensibilidad/resistencia a quinolonas; 5) Identificación de nuevos genes potencialmente implicados en la resistencia a quinolonas y/o virulencia en S. Typhimurium; 6) Comparativa de los genomas de aislados clínicos de S. Typhimurium causantes de salmonelosis invasiva versus no-invasiva procedentes de diferentes áreas geográficas.

APA, Harvard, Vancouver, ISO, and other styles

4

Parte, Aidan Charles. "4-quinolone antibacterials and temperature." Thesis, University College London (University of London), 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.267566.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gropper, Achitoov Savion. "Absorption, safety, and tolerability of a topical quinolone (Absorción, seguridad y tolerabilidad de una quinolona tópica)." Doctoral thesis, Universitat Autònoma de Barcelona, 2015. http://hdl.handle.net/10803/325687.

Full text

Abstract:

Ozenoxacino es una quinolona no fluorada desarrollada como una crema al 1% para el tratamiento tópico del impétigo en adultos y niños (a partir de 2 meses de edad). Ozenoxacino ha demostrado una potente actividad antibacteriana contra diferentes patógenos involucrados en infecciones bacterianas agudas de la piel y estructuras cutáneas. Los estudios de desarrollo preclínico han demostrado que ozenoxacino muestran un amplio margen de seguridad, falta de efectos adversos generalmente asociados con quinolonas fluoradas, (como fototoxicidad, fotoalergia, potencial de sensibilización y toxicidad de tendones y articulaciones) y un bajo potencial de absorción. El desarrollo clínico ha incluido diferentes ensayos clínicos con el fin de evaluar la absorción, seguridad, tolerabilidad y eficacia de aplicaciones tópicas de ozenoxacino. En estos estudios, ozenoxacino ha sido evaluado en diferentes condiciones (diferentes formulaciones, concentraciones, regímenes de administración, duraciones de tratamiento, extensiones de la piel y condiciones de la piel) en voluntarios sanos y en pacientes adultos con lesiones traumáticas secundariamente infectadas, y en pacientes pediátricos y adultos con impétigo. El presente trabajo doctoral incluye los siguientes estudios llevados a cabo para evaluar específicamente la absorción, la seguridad y la tolerabilidad de aplicaciones tópicas de ozenoxacino: • In-vitro percutaneous absorption and metabolism studies. • Systemic bioavailability, safety and tolerability studies. • Skin tissue exposure study. • Dermal tolerability studies. • Systemic bioavailability and safety in impetigo. Estos estudios han sido incluidos en diferentes publicaciones que se presentan y discuten en este trabajo de doctorado. Este trabajo incluye además, una breve revisión de quinolonas, infecciones agudas bacterianas de la piel y estructuras cutáneas, antibióticos tópicos, fármacos en desarrollo para infecciones dermatológicas y ozenoxacino.
Ozenoxacin is a non-fluorinated quinolone currently developed as a 1% cream for the topical treatment impetigo in adults and children (aged 2 months and older). Ozenoxacin has demonstrated a potent antibacterial activity against different pathogens involved in acute bacterial skin and skin structure infections. Preclinical development studies have demonstrated that ozenoxacin show a broad safety margin, a lack of adverse effects usually related to fluorinated quinolones (such as phototoxicity, photoallergenic, sensitizing potential, and tendon and articular toxicity), and a low potential of absorption. The clinical development of ozenoxacin has included different clinical trials to evaluate the absorption, safety, tolerability, and efficacy of topical applications of ozenoxacin. In these studies ozenoxacin has been evaluated under different conditions (different formulations, concentrations, administration regimens, treatment durations, skin extensions and skin conditions) in healthy volunteers and in adult patients with secondarily infected traumatic lesions, and in pediatric and adult patients with impetigo. The present PhD work includes the following clinical studies conducted specifically to evaluate the absorption, safety, and tolerability of ozenoxacin: • In-vitro percutaneous absorption and metabolism studies. • Systemic bioavailability, safety and tolerability studies. • Skin tissue exposure study. • Dermal tolerability studies. • Systemic bioavailability and safety in impetigo. These studies have been published in different papers that are presented and discussed in this PhD work. This work includes as well, a brief review of quinolones, acute bacterial skin and skin structure infections, topical antibiotics, drugs in development for dermatological infections, and ozenoxacin.

APA, Harvard, Vancouver, ISO, and other styles

6

Hodgkinson, James Thomas. "The synthesis of Pseudomonas Quinolone Signal analogues and their effects on quinolone signalling in Pseudomonas aeruginosa." Thesis, University of Cambridge, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.610117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Yvon, Jean-François. "Quinolones - fluoroquinolones : évolution de la résistance, apport des nouvelles molécules." Paris 5, 1998. http://www.theses.fr/1998PA05P047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Le, Bellego Carl. "Sensibilité "in vitro" de "Chlamydia trachomatis" aux antibiotiques : application aux nouvelles quinolones." Paris 5, 1993. http://www.theses.fr/1993PA05P217.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Mitelheiser, Sylvain. "DNA gyrase, quinolone drugs and supercoiling mechanism." Thesis, University of East Anglia, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.423811.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hallett, Paul. "Studies on DNA gyrase and quinolone drugs." Thesis, University of Leicester, 1990. http://hdl.handle.net/2381/35242.

Full text

Abstract:

A study has been conducted aimed at the generation and characterisation of mutations in the Escherichia coli gyrA gene, resistant to the quinolone group of antibacterial agents. Preliminary studies on quinolone-resistant mutants of strains that over-express the DNA gyrA gene, revealed the over-production of a 60 KDa protein which was partially purified. This 60 KDa protein was found to be similar, but not identical to the E. coli heat shock protein GroEL. The gyrA gene has been recloned in the 8.0 kb plasmid pPH3, which contains the gene under the stringent control of the hybrid tac promoter. The E. coli strain JMtacA containing pPH3 exhibits no expression of the gyrA gene in the absence of the inducer (IPTG), but over-produces the protein at greater than 20% of the total soluble cell protein after induction. The optimisation and purification of the GyrA subunit from JMtacA is also described. A fragment was subjected to site-directed mutagenesis which contained the TCG codon for serine-83, which was mutated to alanine (GCG). The mutant showed a 15x increase in MIC50 compared to wild-type. The mutated GyrA subunit was over-produced, complexed with wild-type GyrB subunit and used in various assays for reactions performed by DNA gyrase. The ID50 was determined for supercoiling, decatenation, relaxation of negatively supercoiled DNA, and cleavage of supercoiled DNA. The cleavage reaction mediated by Ca++ was also investigated. The technique of gap-misrepair mutagenesis, geared to the generation of single, random point mutations on a plasmid was also used on the plasmid pPH3, to generate a quinolone-resistant mutant of the gyrA gene. The mutant isolated (GMIOO) was also over-produced and compared to wild-type in various assays. The mutation was determined by DNA sequencing to be glutamine-106 to arginine.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Quinolone"

1

Kuhlmann, J., A. Dalhoff, and H. J. Zeiler, eds. Quinolone Antibacterials. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80364-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

T, Andriole Vincent, ed. The quinolones. London ; San Diego: Academic Press, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hooper, David C., and Ethan Rubinstein, eds. Quinolone Antimicrobial Agents. Washington, DC, USA: ASM Press, 2003. http://dx.doi.org/10.1128/9781555817817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

S, Wolfson John, and Hooper David C, eds. Quinolone antimicrobial agents. Washington, D.C: American Society for Microbiology, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

T, Andriole Vincent, ed. The quinolones. 3rd ed. San Diego: Academic Press, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

1949-, Siporin Clifford, Heifetz Carl L. 1935-, and Domagala John M. 1951-, eds. The New generation of quinolones. New York: M. Dekker, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Susumu, Mitsuhashi, Daikos George K, and International Congress of Chemotherapy, (14th : 1985 : Kyoto), eds. Ofloxacin: A new quinolone antibacterial agent. Tokyo: University of Tokyo Press, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

International Telesymposium on Quinolones (1989). Quinolones: Proceedings of an international telesymposium, May 1989. Barcelona, Spain: J.R. Prous Science Publishers, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ill.) Physicians & Scientists Publishing Co. (Glenview. Gatifloxacin (Tequin): An advanced generation quinolone for the treatment of selected infectious diseases. Glenview, Ill: Physicians & Scientists Pub., 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

R, Ronald Allan, and Low Don E, eds. Fluoroquinolone antibiotics. Boston, Mass: Birkhäuser, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Quinolone"

1

Mitsuhashi, Susumu, Tsuyoshi Kojima, Noriyuki Nakanishi, Teruo Fujimoto, Sachiko Goto, Shuichi Miyazaki, Toshihiko Uematsu, et al. "Fluorinated quinolones — new quinolone antimicrobials." In Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques, 9–147. Basel: Birkhäuser Basel, 1992. http://dx.doi.org/10.1007/978-3-0348-7141-9_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gooch, Jan W. "Quinolone." In Encyclopedic Dictionary of Polymers, 919. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_14631.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Smith, J. T., and H. J. Zeiler. "History and Introduction." In Quinolone Antibacterials, 1–11. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80364-2_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Von Keutz, E., and W. Christ. "Toxicology and Safety Pharmacology of Quinolones." In Quinolone Antibacterials, 297–337. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80364-2_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kuhlmann, J., H. G. Schaefer, and D. Beermann. "Clinical Pharmacology." In Quinolone Antibacterials, 339–406. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80364-2_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Stahlmann, R., and H. Lode. "Concentration—Effect Relationship of the Fluoroquinolones." In Quinolone Antibacterials, 407–20. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80364-2_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schacht, P. "Clinical Use of Quinolones." In Quinolone Antibacterials, 421–53. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80364-2_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Segev, S., and E. Rubinstein. "Future Aspects." In Quinolone Antibacterials, 455–75. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80364-2_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Grohe, K. "The Chemistry of the Quinolones: Methods of Synthesizing the Quinolone Ring System." In Quinolone Antibacterials, 13–62. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80364-2_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Petersen, U., and T. Schenke. "The Chemistry of the Quinolones: Chemistry in the Periphery of the Quinolones." In Quinolone Antibacterials, 63–118. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80364-2_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Quinolone"

1

Vasilyeva, N. Y., and O. V. Vusovich. "Photoprocesses in quinolone substituted." In International Conference on Atomic and Molecular Pulsed Lasers IV, edited by Victor F. Tarasenko, Georgy V. Mayer, and Gueorgii G. Petrash. SPIE, 2002. http://dx.doi.org/10.1117/12.460126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pillai, Shyamala, Laura Wirpsza, Maxim Kozlov, Salvatore A. E. Marras, Lev Krasnoperov, and Arkady Mustaev. "New cross-linking quinoline and quinolone based luminescent lanthanide probes for sensitive labeling." In SPIE BiOS, edited by Samuel Achilefu and Ramesh Raghavachari. SPIE, 2012. http://dx.doi.org/10.1117/12.921056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Andrade, Karine N. de, Amanda R. P. Costa, Rodolfo I. Teixeira, Micaeli L. da S. Moreira, José Walkimar M. Carneiro, Nanci C. L. Garden, Fernanda da C. S. Boechat, Maria Cecília B. V. de Souza, Pedro N. Batalha, and Rodolfo G. Fiorot. "Photophysical characterization of 3-acyl-4-quinolones." In VIII Simpósio de Estrutura Eletrônica e Dinâmica Molecular. Universidade de Brasília, 2020. http://dx.doi.org/10.21826/viiiseedmol202006.

Full text

Abstract:

4-quinolones derivatives can present fluorescent properties, depending on their substituents and on the chemical environment (e.g., acidic medium), allowing their application as ion sensors. We theoretically evaluated the photophysical properties of previously synthesized 3-acyl-4-quinolones to verify how different substituents (R1=H, NH2 and R2 = OEt, OH, NHPh) affect their absorption profiles and the emission profile of a reference compound, PB3. All DFT and TD-DFT calculations were performed at B3LYP-D3/6-311++G(d,p) level and continuum polarization model for simulated acetonitrile as solvent. For PB2 (R1 = H, R2 = OEt), we observed hypsochromic shift compared to PB3 due to the increase of the gap between HOMO/LUMO (absence of electron-donating group), in accordance with experimental data. For R1=NH2 and R2=OH, NHPh (PB6 and PB10, respectively), the gap between HOMO/LUMO increases, resulting in a soft bathochromic shift for the simulated absorption spectra. In addition, we evaluated the effect of acid addition on the absorption and emission profile of PB3 and the results were compared with experimental data. Our thermodynamic results suggest that protonation occurs on the endocyclic carbonyl of the quinolone moiety, probably due to an increased aromatic character, as suggested by our NICS calculations. Finally, we associate the increase of the fluorescence in the acidic medium to the establishment of an intramolecular hydrogen bond and, thus, increased rigidity.

APA, Harvard, Vancouver, ISO, and other styles

4

Wicke, Lena, and Joachim W. Engels. "Synthesis of 6-substituted quinolone nucleosides as potential HIV integrase inhibitors." In XIVth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2008. http://dx.doi.org/10.1135/css200810473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mücke, MM, S. Rüschenbaum, A. Mayer, VT Mücke, KM Schwarzkopf, S. Zeuzem, J. Kehrmann, R. Scholtysik, and CM Lange. "Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis." In 37. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0040-1722014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Shimizu, Kenichiro, Ken Kikuchi, Masayuki Otsuka, and Keiichi Hiramatsu. "Microbiological Features Of Emergent Increase Of Quinolone-Resistant Strains Of Bordetella Pertussis." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Al-Amiery, Ahmed, Mahdi Radi, and Redha AL-Bayati. "Synthesis, spectroscopic and antimicrobial studies of transition metal complexes of N-amino quinolone derivatives." In The 14th International Electronic Conference on Synthetic Organic Chemistry. Basel, Switzerland: MDPI, 2010. http://dx.doi.org/10.3390/ecsoc-14-00435.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Conway, Ruairi, Seamus Cook, Cassandra Malone, Mohammed Osman Hassan-Ibrahim, and Suneeta Soni. "P619 Macrolide and quinolone resistance inmycoplasma genitalium: data from a UK sexual health clinic." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.687.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

González, A., R. González, and M. A. Ferrús. "Antimicrobial susceptibility and quinolone resistance mechanism of Arcobacter butzleri isolates from sewage samples in Spain." In MICROBES IN APPLIED RESEARCH - Current Advances and Challenges. WORLD SCIENTIFIC, 2012. http://dx.doi.org/10.1142/9789814405041_0100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Murray, G. "S03.2 What is the role of quinolone resistance testing in the management of M. genitalium?" In Abstracts for the STI & HIV World Congress, July 14–17 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/sextrans-2021-sti.27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Quinolone"

1

Steele, W., and R. Chirico. Thermodynamics of the hydrodenitrogenation of quinoline. Office of Scientific and Technical Information (OSTI), June 1990. http://dx.doi.org/10.2172/6958305.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gunsaru, Bornface. Simplified Reversed Chloroquines to Overcome Malaria Resistance to Quinoline-based Drugs. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.400.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Wang, Hong, Eric Wolfe, Edgar Lara-Curzio, Marco Martinez, and Tracie Lowe. Study on Electrostatic Separation of Quinoline Insolubles from Coal Tar Pitch. Office of Scientific and Technical Information (OSTI), March 2023. http://dx.doi.org/10.2172/1960688.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Steele, W., S. Knipmeyer, and R. Chirico. Critical property and high-temperature heat-capacity measurements on quinoline and 5,6,7,8-tetrahydroquinoline. Office of Scientific and Technical Information (OSTI), June 1990. http://dx.doi.org/10.2172/6957875.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chaudhuri, Shubham, Pinelopi Goldberg, and Panle Jia. Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India. Cambridge, MA: National Bureau of Economic Research, December 2003. http://dx.doi.org/10.3386/w10159.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bradshaw, Jerald S., Guoping Xue, Xian X. Zhang, Paul B. Savage, and Krzysztof E. Krakowiak. Bis-(quinolin-8-ylmethyl)-substituted Diaza-18-crown-6: Synthesis and Metal Ion Complexation Properties. Fort Belvoir, VA: Defense Technical Information Center, March 2000. http://dx.doi.org/10.21236/ada375274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!